Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising therapeutic option, particularly for refractory and relapsed leukemias. However, its efficacy in treating solid tumors, including lung, ovarian, gastric, and breast cancers, remains limited by several challenges. Recent studies have highlighted...
Qian Niu, Meng Li, Cheng-Yi Zhang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.